Lynsight

Lynsight Improving outcomes through reliable Lynch syndrome diagnostics and raising cancer risk awareness.

What an unforgettable few days! The 2025 -GGC Annual Meeting marked a major milestone: 30 years of progress, collaborati...
13/11/2025

What an unforgettable few days! The 2025 -GGC Annual Meeting marked a major milestone: 30 years of progress, collaboration, and innovation in the fight against hereditary GI cancer syndromes.

Since 1995, CGA-IGC has built a global community of clinicians, researchers, and advocates dedicated to advancing prevention, diagnosis, and treatment. This year, that spirit was stronger than ever, as we gathered in St. Louis to reflect on our shared history and look boldly toward the future of care.

Thank you to everyone who participated, presented, and contributed to this incredible event. Together, we’re shaping the next chapter in hereditary GI cancer research and care.

If you missed the event, visit our site to learn more about Lynch sydrome testing: https://lynsightlabs.com/lynch-syndrome-testing/

12/11/2025

Clarity starts here. At Lynsight, we give you answers, not maybes. Take control of your health with straightforward, reliable testing for Lynch syndrome.

Your future shouldn't be a question mark. Ask Lynsight: https://lynsightlabs.com/

🚨 Last call! Do you want to help raise Lynch syndrome awareness and advance life-saving testing? Here’s your chance to s...
10/11/2025

🚨 Last call!

Do you want to help raise Lynch syndrome awareness and advance life-saving testing? Here’s your chance to support the transformation of hereditary cancer diagnostics.

Our patented DiagMMR technology is a true breakthrough: a tumor-independent test capable of detecting Lynch syndrome, the most common hereditary cancer syndrome, before cancer develops. With 94% accuracy demonstrated in Finland, DiagMMR is now on a clear path toward FDA regulatory approval, with U.S. commercialization planned for early 2027.

Help us make early detection accessible for everyone.

Invest today in the future of Lynch syndrome testing:
https://www.invesdor.com/rounds/1138a782-88f7-44bf-8874-fedc8c49a374 #/

New Day Diagnostics

We’re proud to announce our strategic partnership with New Day Diagnostics, a leading innovator in diagnostic solutions,...
06/11/2025

We’re proud to announce our strategic partnership with New Day Diagnostics, a leading innovator in diagnostic solutions, to initiate clinical studies and accelerate U.S. market access for DiagMMR, our proprietary diagnostic test for identifying mismatch repair deficiencies, the key biomarker in Lynch syndrome.

This milestone marks a major step in our mission to expand access to advanced diagnostics and improve early detection of hereditary cancer syndromes. Together, we’re combining clinical validation, research infrastructure, and shared expertise to bring DiagMMR to healthcare providers and patients across the U.S.

Clinical studies are set to begin in early 2026 with top-tier U.S. institutions, paving the way for FDA authorization and nationwide impact.

Read the full press release to learn more about the partnership: https://lynsightlabs.com/lynsight-announces-strategic-partnership-with-new-day-diagnostics-to-advance-diagmmr-clinical-studies-in-the-united-states/

Early detection saves lives.Lynch syndrome is one of the most common inherited conditions, and often goes undiagnosed.By...
04/11/2025

Early detection saves lives.

Lynch syndrome is one of the most common inherited conditions, and often goes undiagnosed.

By prioritizing preventative health and genetic testing, we can identify risk early and take action before cancer develops.

Learn more about the impact of Lynch syndrome testing → https://lynsightlabs.com/lynch-syndrome-testing/

Exciting news from Lynsight!We’re excited to announce that Lynsight has officially opened its public investment round, o...
31/10/2025

Exciting news from Lynsight!

We’re excited to announce that Lynsight has officially opened its public investment round, offering a chance to join a company that is redefining hereditary cancer diagnostics. Our patented DiagMMR technology represents a true breakthrough: a tumor-independent test that can detect Lynch syndrome, the most common hereditary cancer syndrome, before cancer develops. With 94% accuracy demonstrated in Finland, DiagMMR is now on a clear path toward FDA regulatory approval, with U.S. commercialization planned for early 2027.

Join us in making early detection accessible for all. 💙

Invest in the future of Lynch sydrome testing: https://www.invesdor.com/rounds/1138a782-88f7-44bf-8874-fedc8c49a374 #/

Did you know that genetic testing for Lynch syndrome may be covered by insurance?If you have a personal or family histor...
30/10/2025

Did you know that genetic testing for Lynch syndrome may be covered by insurance?

If you have a personal or family history of related cancers, you may qualify. Check with your insurance provider to learn more about your coverage options.

Take the first step. Know your risk. https://lynsightlabs.com/lynch-syndrome-testing/

28/10/2025

With DiagMMR, healthcare providers gain a powerful, precise tool to identify at-risk individuals early, enabling preventive care and life-saving outcomes.

Advanced Lynch syndrome diagnostics start here. Learn more about how you can provide the best testing for your patients → https://lynsightlabs.com/for-providers/

2 million cancer cases should be tested for Lynch syndrome every year. Testing enables preventive strategies, lifestyle ...
23/10/2025

2 million cancer cases should be tested for Lynch syndrome every year.

Testing enables preventive strategies, lifestyle changes, and protects entire families from inherited risk.

Don’t wait. Start the conversation about Lynch syndrome testing today. Learn more at https://lynsightlabs.com/about-lynch-syndrome/

Osoite

ArabianKatu 12
Helsinki
00560

Aukioloajat

Maanantai 09:00 - 17:00
Tiistai 09:00 - 17:00
Keskiviikko 09:00 - 17:00
Torstai 09:00 - 17:00
Perjantai 09:00 - 17:00

Puhelin

+358406602622

Nettisivu

Hälytykset

Tiedä ensimmäisenä ja anna meille oikeus lähettää sinulle sähköpostitse uutisia ja promootioita Lynsight :ltä. Sähköpostiosoitettasi ei käytetä muihin tarkoituksiin, ja voit perua milloin tahansa.

Oikopolut

Jaa

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Kategoria